Delisting risk
Radiopharm Theranostics (ADR) (RADX)
Develops targeted radiopharmaceutical diagnostics and therapies for solid tumors.
$2.02
Pre-market−0.11 (−5.16%)
At close$2.13(−6.17%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions7 holders · as of Mar 31, 2026 | 3,982.92% | 51.31M ADS | |
| Adds to | 3,982.92% |
1.29M ADS as of Aug 21, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Some positions are filed in underlying shares, not receipts; the ratio is unknown, so no percentage.
These groups come from separate filings that can overlap, so they add to 3,982.92%; nothing is left for Other.
Institutions13F, as of Mar 31, 2026
7 holders · 51.31M shares · 0 new positions · 1 increased · 3 reduced · 4 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Stonepine Capital Management, LLC | 51.00M | 3,959.01% | 0 | May 14, 2026 |
| Silverarc Capital Management, LLC | 187.4K | 14.55% | 0 | May 14, 2026 |
| HSBC Holdings PLC | 61.4K | 4.76% | −130.3K | Apr 30, 2026 |
| Regal Partners Ltd | 40.1K | 3.12% | −50.8K | May 15, 2026 |
| PNC Financial Services Group, Inc. | 16.0K | 1.24% | 0 | May 8, 2026 |
| UBS Group AG | 3.0K | 0.23% | −11.3K | May 5, 2026 |
| Rhumbline Advisers | 121 | 0.01% | +115 | May 12, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Regal Partners Holdings Pty Limited | 9.05% | 13G | Jan 8, 2026 ↗ | |
| Regal Funds Management Pty Limited | 7.30% | 13G | Jul 23, 2025 ↗ |
Insider tradesForm 4
Latest trades
Nothing filed in the last 12 months.
CongressHouse and Senate disclosures
Not reported.